Abstract
Background: In rectal cancer, 5FU is currently used to increase tumor sensitivity to radiotherapy (RT).However, it induces treatment-related toxicity. Surprisingly,the use of metformin has beenassociated with increased tumor response rates to 5FU-based chemoradiation. In this setting,metformin could be used an alternative radiosensitizing agent to 5FU to optimize tumor responsebut minimal treatment-related toxicity. An experimental study was designed to estimate tumorregression effects in vivo after RT+5FU and RT+metformin.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
